William A Bye1, Christopher Ma1,1, Tran M Nguyen1,1, Claire E Parker1,1, Vipul Jairath1,1,1, James E East1. 1. Department of Gastroenterology and Hepatology, Prince of Wales Hospital, Sydney, NSW, Australia. Division of Gastroenterology and Hepatology, University of Calgary, Calgary, AB, Canada. Robarts Clinical Trials, Western University, London, ON, Canada. Cochrane Inflammatory Bowel Disease Group, Robarts Clinical Trials, London, ON, Canada. Department of Medicine, Western University, London, ON, Canada. Department of Epidemiology and Biostatistics, Western University, London, ON, Canada. Translational Gastroenterology Unit, Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK. These authors contributed equally: William A. Bye and Christopher Ma.
Abstract
OBJECTIVES: Patients with longstanding ulcerative colitis (UC) and colonic Crohn's disease (CD) have an increased risk of colorectal cancer (CRC). We assess the effectiveness of endoscopic surveillance in patients with inflammatory bowel disease (IBD) for diagnosing CRC and reducing CRC-related mortality. METHODS: MEDLINE, EMBASE, and CENTRAL were searched from inception to 19 September 2016. Randomized controlled trials (RCTs), observational cohorts, or case-control studies assessing any form of endoscopic surveillance for early CRC detection were eligible for inclusion; studies without a comparison non-surveillance group were excluded. The primary outcome was rate of CRC detection. Secondary outcomes were rate of early (Duke stage A and B) versus late (Duke stage C & D) CRC detection and rate of CRC-related death. Data were pooled using fixed or random effects models based on the degree of heterogeneity; pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using the Mantel-Haenszel method. RESULTS: Five observational studies evaluating 7199 IBD patients were included; no RCTs met criteria for inclusion. There are limited new studies evaluating this clinical question (last included study published 2014). There was a significantly higher rate of cancer detection in the non-surveillance group (3.2%, 135/4256) compared to the surveillance group (1.8%, 53/2895) (OR 0.58 (95% CI: 0.42-0.80), p < 0.001). In four pooled studies, there was a significantly lower rate of CRC-associated death in the surveillance group (8.5%, 15/176) compared to the non-surveillance group (22.3%, 79/354) (OR 0.36 (95% CI: 0.19-0.69), p = 0.002). In two pooled studies, there was a significantly higher rate of early-stage CRC detection in the surveillance group (15.5%, 17/110) compared to the non-surveillance group (7.7%, 9/117) (OR 5.40 (95% CI: 1.51-19.30), p = 0.009). CONCLUSIONS: Colonoscopic surveillance in IBD is associated with a reduction in CRC development and CRC-associated death, as well as increased detection of early-stage CRC.
OBJECTIVES:Patients with longstanding ulcerative colitis (UC) and colonic Crohn's disease (CD) have an increased risk of colorectal cancer (CRC). We assess the effectiveness of endoscopic surveillance in patients with inflammatory bowel disease (IBD) for diagnosing CRC and reducing CRC-related mortality. METHODS: MEDLINE, EMBASE, and CENTRAL were searched from inception to 19 September 2016. Randomized controlled trials (RCTs), observational cohorts, or case-control studies assessing any form of endoscopic surveillance for early CRC detection were eligible for inclusion; studies without a comparison non-surveillance group were excluded. The primary outcome was rate of CRC detection. Secondary outcomes were rate of early (Duke stage A and B) versus late (Duke stage C & D) CRC detection and rate of CRC-related death. Data were pooled using fixed or random effects models based on the degree of heterogeneity; pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using the Mantel-Haenszel method. RESULTS: Five observational studies evaluating 7199 IBD patients were included; no RCTs met criteria for inclusion. There are limited new studies evaluating this clinical question (last included study published 2014). There was a significantly higher rate of cancer detection in the non-surveillance group (3.2%, 135/4256) compared to the surveillance group (1.8%, 53/2895) (OR 0.58 (95% CI: 0.42-0.80), p < 0.001). In four pooled studies, there was a significantly lower rate of CRC-associated death in the surveillance group (8.5%, 15/176) compared to the non-surveillance group (22.3%, 79/354) (OR 0.36 (95% CI: 0.19-0.69), p = 0.002). In two pooled studies, there was a significantly higher rate of early-stage CRC detection in the surveillance group (15.5%, 17/110) compared to the non-surveillance group (7.7%, 9/117) (OR 5.40 (95% CI: 1.51-19.30), p = 0.009). CONCLUSIONS: Colonoscopic surveillance in IBD is associated with a reduction in CRC development and CRC-associated death, as well as increased detection of early-stage CRC.
Authors: Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann Journal: BMJ Date: 2008-04-26
Authors: Chang-Ho R Choi; Ibrahim Al Bakir; Ailsa L Hart; Trevor A Graham Journal: Nat Rev Gastroenterol Hepatol Date: 2017-02-08 Impact factor: 46.802
Authors: Christopher Ma; Rowan Lumb; Emily V Walker; Rae R Foshaug; ThucNhi T Dang; Sanam Verma; Vivian W Huang; Karen I Kroeker; Karen Wong; Levinus A Dieleman; Richard N Fedorak; Brendan P Halloran Journal: Inflamm Bowel Dis Date: 2017-09 Impact factor: 5.325
Authors: Maurice W M D Lutgens; Martijn G H van Oijen; Geert J M G van der Heijden; Frank P Vleggaar; Peter D Siersema; Bas Oldenburg Journal: Inflamm Bowel Dis Date: 2013 Mar-Apr Impact factor: 5.325
Authors: Chang-ho Ryan Choi; Ana Ignjatovic-Wilson; Alan Askari; Gui Han Lee; Janindra Warusavitarne; Morgan Moorghen; Siwan Thomas-Gibson; Brian P Saunders; Matthew D Rutter; Trevor A Graham; Ailsa L Hart Journal: Am J Gastroenterol Date: 2015-09-29 Impact factor: 10.864
Authors: Anouk M Wijnands; Maarten Te Groen; Yonne Peters; Ad A Kaptein; Bas Oldenburg; Frank Hoentjen; Maurice W M D Lutgens Journal: Inflamm Bowel Dis Date: 2022-07-01 Impact factor: 7.290
Authors: Jakob Weglage; Friederike Wolters; Laura Hehr; Jakob Lichtenberger; Celina Wulz; Felix Hempel; Anne Baier; Thomas Quack; Kernt Köhler; Thomas Longerich; Gabriele Schramm; Karuna Irungbam; Heike Mueller; Verena von Buelow; Annette Tschuschner; Margarete Odenthal; Uta Drebber; Maha El Arousy; Leandra N Z Ramalho; Katrin Bankov; Peter Wild; Jörn Pons-Kühnemann; Jonas Tschammer; Christoph G Grevelding; Elke Roeb; Martin Roderfeld Journal: Sci Rep Date: 2020-12-23 Impact factor: 4.379
Authors: Gaurav Syal; Mariastella Serrano; Animesh Jain; Benjamin L Cohen; Florian Rieder; Christian Stone; Bincy Abraham; David Hudesman; Lisa Malter; Robert McCabe; Stefan Holubar; Anita Afzali; Adam S Cheifetz; Jill K J Gaidos; Alan C Moss Journal: Inflamm Bowel Dis Date: 2021-10-18 Impact factor: 5.325